Other languages Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.712 ^USD	-2.51%		-3.51%	-47.26%

May. 15	Transcript : Biora Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
May. 15	Earnings Flash (BIOR) BIORA THERAPEUTICS Reports Q1 Revenue $542,000	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	Apr. 30
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	Apr. 04
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	Apr. 02
Top Midday Decliners	Apr. 01
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	Feb. 26
Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600	Jan. 08
Biora Therapeutics, Inc. Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform with AstraZeneca	Jan. 02
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	Dec. 20
Biora Therapeutics, Inc. Announces New Research Collaboration for the Biojet Systemic Oral Delivery Platform	Dec. 11
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Dec. 01
Top Premarket Gainers	Dec. 01
Biora Therapeutics Says FDA Cleared Application for Investigational Ulcerative Colitis Treatment; Shares Rise Pre-Bell	Dec. 01
Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis	Nov. 30
Biora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Biora Therapeutics to Submit Updated Application to FDA for BT-600	23-10-23
Biora Therapeutics Presents Data on the Biojet? Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes	23-10-05
Biora Therapeutics Shares Rise After BioJet Platform Achieves Performance Target	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Other languages

Filters